ETNB - 89bio mid-stage trial of pegozafermin meets primary endpoint for high triglycerides

A phase 2 trial of 89bio's (NASDAQ:ETNB) pegozafermin met its primary endpoint as a treatment of severe hypertriglyceridemia. Patients on pegozafermin saw clinically meaningful and significant reductions in triglycerides from baseline through week 8 across all doses. The highest dose saw the greatest reduction, 63%. The candidate, which is given once a week, also led to reductions in liver fat and improvements in glycemic control markers, both of which can influence cardiovascular risk, Those on background therapy -- such as a statin drug or fish oil pills -- saw even greater triglyceride reductions. Also, those taking pegozafermin also saw an improvement in HDL levels, also known as "good cholesterol." Pegozafermin is also under development for non-alcoholic steatohepatitis (NASH). 89bio garners a hold rating from Seeking Alpha's Quant Rating with poor grades for growth, profitability, and momentum.

For further details see:

89bio mid-stage trial of pegozafermin meets primary endpoint for high triglycerides